Neurogene Inc. (NGNE) Debt Components
- 2014-12-31: Long-term Line of CreditUSD (m); Line of Credit Facility, Increase, Accrued InterestUSD 12 month · $9.84K; Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)USD (m).
- 2014-09-30: Long-term Line of CreditUSD (m); Line of Credit Facility, Increase, Accrued InterestUSD 9 month · $9.84K; Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)USD (m).
- 2014-09-30: Long-term Line of CreditUSD $0.00; Line of Credit Facility, Increase, Accrued InterestUSD (m); Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)USD (m).
- 2014-06-30: Long-term Line of CreditUSD (m); Line of Credit Facility, Increase, Accrued InterestUSD 6 month · $9.84K; Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)USD (m).
Neurogene Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Line of Credit USD | Line of Credit Facility, Increase, Accrued Interest USD | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|
| 2014-12-31 | (m) | 12 month · $9.84K | (m) |
| 2014-09-30 | (m) | 9 month · $9.84K | (m) |
| 2014-09-30 | $0.00 | (m) | (m) |
| 2014-06-30 | (m) | 6 month · $9.84K | (m) |
| 2014-06-30 | $0.00 | (m) | (m) |
| 2014-03-31 | (m) | 3 month · $9.84K | (m) |
| 2013-12-31 | $2.29M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $2.29M |
| 2012-12-31 | $0.00 | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |